CN110283231B

CN110283231B - Preparation and application of novel lyotropic liquid crystal based on amphiphilic oligopeptide self-assembly

Info

Publication number: CN110283231B
Application number: CN201910475542.7A
Authority: CN
Inventors: 秦四勇; 丁文强; 雷新响; 张爱清
Original assignee: South Central University for Nationalities
Current assignee: South Central Minzu University
Priority date: 2019-06-03
Filing date: 2019-06-03
Publication date: 2021-04-27
Anticipated expiration: 2039-06-03
Also published as: CN110283231A

Abstract

The invention relates to preparation and application of a novel self-assembly lyotropic liquid crystal based on amphiphilic oligopeptide, wherein the oligopeptide has a structure

The method adds the oligopeptide into a dimethyl sulfoxide (DMSO) solvent, and the oligopeptide molecules can generate ordered nano fibers through non-covalent action after ultrasonic dispersion. Meanwhile, the assembly system shows a specific ordered structure and good fluidity, can be used as a novel lyotropic liquid crystal medium to measure residual dipolar coupling values (RDCs) of biomolecules, and realizes the analysis of the molecular structure based on Nuclear Magnetic Resonance (NMR) detection. The oligopeptide can be automatically synthesized by an instrument and is easy to prepare; the liquid crystal medium can be prepared by directly dissolving the oligopeptide, and the method is simple and has strong operability. In addition, the solvent in the system is DMSO, so that the problem that the detected substrate cannot be dissolved in the conventional solvent can be effectively solved, and the variety and the number of the detected substrates are effectively expanded.

Description

Preparation and application of novel lyotropic liquid crystal based on amphiphilic oligopeptide self-assembly

Technical Field

The invention relates to the technical field of biological materials, in particular to preparation and application of a novel lyotropic liquid crystal based on self-assembly of amphiphilic oligopeptides.

Background

Liquid Crystal (LC) materials have wide applications in the field of biological tissues and in synthetic systems due to their own order and mobility. For example, in biological tissues, the ordered arrangement and fluidity of LC can play a crucial role in the formation of tissue structures in vivo. In recent years, artificially synthesized liquid crystal systems also show wide application prospects. The ordered nanostructure inside the LC can provide good channels for ion and electron transport, and defects in its topology can guide molecular self-assembly and the orientation of inorganic particles. In addition, the LC template can mediate the directional growth of other materials, thereby preparing novel ordered nano and sub-nano materials. Therefore, the construction of the functional liquid crystal system has important application value.

Currently, scientists have found that a variety of polymers such as DNA, cellulose, polypeptides, etc. can form LC materials. However, liquid crystal materials prepared via polymers often involve harsh or cumbersome preparation methods. For example: to ensure that the polymer liquid crystals achieve an internal efficient orientation at low concentrations, the molecular weight of the polymer must be large, which involves harsh synthesis conditions. Therefore, relying on simple molecules to prepare LCs has attracted considerable interest to researchers. Recently, LC materials based on low molecular weight compounds have emerged rapidly. Among them, oligopeptides are receiving attention in the field of low molecular weight liquid crystals due to their simple and mature synthesis method, diversity of sequence structure and strong self-assembly ability. Research shows that the oligopeptide can self-assemble in solvents such as methanol, carbon disulfide, water and the like to form various lyotropic liquid crystals by adjusting the sequence structure of the peptide. However, the construction of lyotropic oligopeptides LC using pure dimethyl sulfoxide (DMSO) as a solvent has not been solved, because oligopeptides are difficult to self-assemble in DMSO to form an ordered structure. In addition, in these established oligopeptide LC systems, the structures must contain rigid fragments containing aromatic ring residues such as phenylalanine and tyrosine. Therefore, if a DMSO-compatible flexible oligopeptide liquid crystal can be constructed, not only can a basis be provided for designing a novel liquid crystal without a rigid group, but also the new performance of the lyotropic liquid crystal based on a DMSO solvent as a system can be researched.

Disclosure of Invention

In order to solve the technical problems, the invention provides a novel lyotropic liquid crystal based on self-assembly of amphiphilic oligopeptides and a preparation method thereof, and aims to provide a novel flexible amphiphilic oligopeptide which can be assembled in pure DMSO to realize the construction of a DMSO-compatible compliant oligopeptide liquid crystal system. The lyotropic LC has good fluidity and orientation, and can be used as an ordered medium for accurate measurement of biomolecule RDCs. Because DMSO used in the liquid crystal is a good solvent for many molecules, and DMSO-d6 is a common deuterated reagent, the liquid crystal system effectively expands the range of the tested substrate based on nuclear magnetic detection.

The invention provides a novel lyotropic liquid crystal based on self-assembly of amphiphilic oligopeptide, which is characterized in that the oligopeptide is shown as a structural formula (I):

as a further improvement of the invention, the novel lyotropic liquid crystal is prepared by self-assembling based on the amphipathic oligopeptide, and adding the oligopeptide into a DMSO solvent for ultrasonic full dissolution.

As a further improvement of the invention, the liquid crystal is assembled by oligopeptide in pure DMSO solvent.

As a further improvement of the invention, the liquid crystal shows residual quadrupole coupling of 5-76Hz at deuterium resonance in DMSO-d6 solution at oligopeptide concentration of 2-10 wt%.

The invention further protects the application of the RDCs for accurately measuring the biomolecules by taking the novel lyotropic liquid crystal self-assembled based on the amphiphilic oligopeptide as an ordered medium.

As a further improvement of the invention, the liquid crystal can measure the RDCs of biomolecules dissolved in DMSO, and thereby analyze the structure thereof.

As a further improvement of the invention, the liquid crystal can measure the RDCs of the estrone and analyze the structure of the estrone.

As a further improvement of the invention, the liquid crystal can measure the RDCs of the 10-hydroxycamptothecin and analyze the structure of the 10-hydroxycamptothecin.

As a further improvement of the invention, the medium can measure the RDCs of the artemisinin and analyze the structure of the artemisinin.

The invention has the following beneficial effects:

1. the lyotropic LC of the invention is constructed by self-assembly of oligopeptide amphiphiles (OPA) in DMSO. The oligopeptides are composed entirely of flexible chains and do not contain rigid aromatic groups. Deuterium resonance of 2 wt% of the oligopeptide in DMSO showed RQC at 5Hz, and RQC at a concentration of 10 wt% was 76 Hz. The low concentration, high RQC indicates that the self-assembled OPA fiber has highly oriented properties and is an ideal ordered medium for measuring the biomolecule RDCs.

2. The oligopeptide chain prepared by the invention does not contain rigid aromatic groups, and avoids the possible pi-pi interaction between an ordered medium and an analysis substrate, so that the lyotropic LC can be used for RDCs (radio frequency Cs) measurement of aromatic molecules such as antitumor drugs 10-hydroxycamptothecin and estrone.

3. The solvent of the self-assembly oligopeptide LC is pure DMSO, so that the preparation of the oligopeptide LC with the pure DMSO as the solvent is realized, the variety of analytes is greatly expanded, and as for a common deuterated reagent, a plurality of molecules can only be dissolved in DMSO-d6 for RDCs measurement.

Drawings

FIG. 1 is a schematic diagram of the self-assembly of OPA prepared by the present invention into nanofibers in DMSO;

FIG. 2 is a diagram of a matrix-assisted laser desorption time-of-flight mass spectrometer (MALDI-TOFMS) for OPA prepared in example 1 of the present invention;

FIG. 3 is a High Performance Liquid Chromatography (HPLC) chart of OPA prepared in example 1 of the present invention, with a purity of 95.67%;

FIG. 4 is a Dynamic Light Scattering (DLS) spectrum of OPA prepared in example 1 of the present invention;

FIG. 5 is a Scanning Electron Microscope (SEM) image of 0.5 wt% OPA prepared according to example 1 of the present invention;

FIG. 6 is an SEM image of a 4.0 wt% OPA preparation of example 1 of the present invention;

FIG. 7 is a plot of the Small Angle X-ray Scattering (SAXS) of OPA prepared in example 1 of the present invention;

FIG. 8 shows OPA prepared according to example 1 of the present invention in DMSO-d6(1 wt%)¹HNMR (600MHz) spectrum (a), infrared (FT-IR) spectrum (B) of OPA fiber prepared in inventive example 1, wide angle X-ray diffraction (WXRD) curve (C) of self-assembled OPA fiber prepared in inventive example 1;

FIG. 9 is a photograph of cross-polarized filters in a nuclear magnetic tube of self-assembled OPALC prepared in example 1 of the present invention;

FIG. 10 is a texture map of nematic liquid crystals under a polarizing microscope (POM) for OPALCs prepared according to example 1 of the present invention at different concentrations;

FIG. 11 is a two-dimensional (2D) SAXS plot of OPALC prepared in example 1 of the present invention;

FIG. 12 shows deuterium (D) of OPALC prepared according to example 1 of the present invention at various concentrations²H) NMR chart;

FIG. 13 shows a solution of 10mg of estrone in OPALC (LC concentration 40.0mg/mL) prepared in example 1 of the present invention²A HNMR map;

FIG. 14 is a schematic view of a recording medium of estrone using the self-assembled liquid crystal prepared in example 1 of the present invention as an ordered medium¹H,¹³C]-JSB-HSQC spectrum;

FIG. 15 is a graph showing the fitted linear relationship between the RDCs of the measured estrone and the calculated RDCs using the self-assembled liquid crystal prepared in example 1 of the present invention as an ordered medium;

FIG. 16 shows the results of 10mg 10-hydroxycamptothecin dissolved in OPALC (LC concentration 40.0mg/mL) prepared in example 1 of the present invention²A HNMR map;

FIG. 17 records the value of 10-hydroxycamptothecin using the self-assembled LC prepared in example 1 of the present invention as an ordered Medium¹H,¹³C]-JSB-HSQC spectrum;

FIG. 18 shows a solution of 10mg of artemisinin in OPALC (LC concentration 40.0mg/mL) prepared in example 3 of the present invention²A HNMR map;

FIG. 19 is a self-assembled LC prepared using example 1 of the present invention as an ordered medium for recording artemisinin¹H,¹³C]-JSB-HSQC spectrum;

FIG. 20 is a graph of the fitted linear relationship between the measured RDCs of 10-hydroxycamptothecin and the calculated RDCs using the self-assembled liquid crystal prepared in example 1 of the present invention as an ordered medium;

FIG. 21 is a graph of the fitted linear relationship between artemisinin-measuring RDCs and calculated RDCs using the self-assembled liquid crystal prepared in example 1 of the present invention as an ordered medium.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention and the accompanying drawings, and it is obvious that the embodiments are only some representative embodiments of the present invention, rather than all embodiments, and all other embodiments obtained by a person skilled in the art without any creative work belong to the protection scope of the present invention.

Example 1

The amphiphilic oligopeptide is palmitic acid-alanine-lysine-glutamic acid (C)₁₅H₃₁-CONH-AAAAAKEE-CONH₂) Synthesized by standard FMOC chemical solid phase polypeptide synthesis.

The invention also provides a preparation method of the novel lyotropic liquid crystal based on self-assembly of the amphiphilic oligopeptide, which comprises the following steps: and adding the oligopeptide chain into a DMSO solution, and performing ultrasonic full dissolution to obtain the oligopeptide.

Wherein the structure of the obtained Oligopeptide (OPA) is as follows:

the invention detects the accurate molecular weight of OPA through MALDI-TOFMS. The test results are shown in fig. 2, the abscissa represents the mass-to-charge ratio, and the ordinate represents the relative intensity of the ion current, (m/z (%): OPA: 997.76(100) [ M ]]⁺，(m/z(％))：OPA：1019.75(100)[M+Na]⁺，(m/z(％))：OPA：1035.72(100)[M+K]⁺. The accuracy of the structure is verified by comparing the experimental value with the theoretical molecular weight. Further, the purity of the synthesized OPA was analyzed by high performance liquid chromatography, and the analysis test result showed a single peak having a purity of 95.67%, and the analysis result is shown in fig. 3, in which the abscissa represents the retention time and the ordinate represents the electric signal.

The self-assembly of OPA into nanofibers in DMSO is shown in figure 1. Notably, self-assembled nanofibers exhibit good ordering and lyotropic LC behavior in this organism system. It has been found through research that such an ordered medium can orient biomolecules and restrict their molecular motion, which is beneficial for capturing the RDCs of the molecules.

To investigate initially whether OPA can spontaneously assemble in DMSO, the present invention first evaluated the self-assembly of OPA in DMSO by DLS, and showed two peaks at 120nm and 550nm, as shown in fig. 4, where the abscissa indicates the particle size and the ordinate indicates the relative intensity, and the presence of aggregates can be shown from fig. 4.

Further, the morphology of the self-assembled nanofiber is observed by SEM imaging, the observed morphology is shown in FIG. 5, and 0.5 wt% of OPA is self-assembled into fibrous nanowires with the average diameter of about 70nm in DMSO. It can be observed by observation that the nanowires exhibit an ordered alignment state. After increasing the OPA content to 4.0 wt%, the diameter of the nanowires became smaller, as shown in fig. 6. SAXS was used to measure the size of self-assembled nanowire dimensions in DMSO solutions. When the OPA content is less than 4 wt%, only a close approximation to that observed in the scattering diagram is observed

The peak of (a), fig. 7, indicates that the similar nanowires have a diameter of about 6.2nm, with the abscissa in fig. 7 representing the q-value and the ordinate representing the relative intensity. Thus, the nanowires observed from the SEM images all consisted of several individual nanofibers. Meanwhile, when the OPA content exceeds 4%, it is found to be close to

There is a new signal peak whose high q value is probably due to the OPA molecule size of 3.8 nm.

In order to explore the intermolecular interaction force of the self-assembly of OPA in DMSO, the invention monitors the chemical shift of amide protons at different temperatures by NMR to determine whether hydrogen bonds are involved. As shown in fig. 8A, an increase in temperature from 293K to 323K resulted in a shift of the amide protons of the peptide backbone from a low field to a high field. However, the chemical shifts of the other protons are not affected. This result suggests that hydrogen bonding is involved in peptide self-assembly. Furthermore, the FT-IR spectrum of lyophilized OPA was 3295cm^-1The characteristic absorption peak (amide a) shown there, as shown in figure 8B,which is designated as NH oscillation associated with hydrogen bonding. In fig. 8B, wavenumber indicates wavelength and intensity indicates relative intensity.

In addition, FT-IR spectroscopy also provides information on the molecular arrangement in OPA nanofibers. FT-IR spectrum was shown at 1628cm^-1And 1540cm^-1Two nearby stretching vibration peaks, which correspond to the characteristic absorption peaks of amides I and II in the β -sheet. At the same time, the 21 ° diffraction peak in the WXRD curve also indicates the beta-sheet secondary conformation of the nanofibers, as shown in fig. 8C.

The self-assembled nanofiber solution was poured into an NMR tube and its fluidity and birefringence main characteristics were observed through two cross-polarizing filters. The significant birefringence properties can be seen in fig. 9. Different concentrations of OPALC were dropped onto the slides and a typical nematic liquid crystal texture was observed by POM as shown in FIG. 10. The appearance of nematic liquid crystal texture depends on the OPA concentration (>4.0 wt%). In addition, the two-dimensional SAXS pattern of 10 wt% OPA produced an elliptical diffusion pattern with high axial ratio, as in fig. 11, indicating that OPA nanofibers have ordered character. As the peptide concentration increased, the corresponding 2D pattern showed a typical diffuse arc of reflection due to bragg reflection.

To further confirm the liquid crystalline properties of the nanofiber solution, deuterium (ll) was added²H) NMR confirmed the ordered arrangement. At 600 MHz: (¹H) In the spectrometer, deuterium resonance of 2 wt% OPA in DMSO-d6 solution showed a residual quadrupole coupling value of 5Hz, indicating that the nanofibers in solution have some orientation. A positive correlation was observed between the RQC value of OPA in DMSO-d6 and its concentration. When the OPA concentration was 10 wt%, its RQC was 76Hz, as shown in FIG. 12, where the abscissa in FIG. 12 represents frequency and the ordinate represents relative intensity. In nuclear magnetism²The signal of the H quadrupole splitting is highly symmetric with a half-width of 2.5Hz, and a relatively narrow half-width indicates less viscous from the side. OPA self-assembled LC shows excellent order and mobility, which suggests that OPALC has great potential as an ideal ordered medium for measuring biomolecular RDCs.

Example 2

To investigate the applicability of self-assembled LC as a mediator to accurately obtain RDCs in DMSO-d6, studies using estrone containing aromatic rings as a model molecule were performed below.

Wherein, the structural formula of the estrone is shown as the following formula (II), and the spectrum of C-13 is shown in the table 1.

TABLE 1C-13 Spectroscopy of estrones

As shown in FIG. 13, 10.0mg of estrone was dissolved in OPALC (LC concentration of 40.0mg/mL), which was²The HNMR spectrum showed RQC to be 20.42 Hz. In fig. 13, the abscissa represents frequency and the ordinate represents relative intensity. [1H, 13C ] for the recording of estrone using self-assembled LC as ordered medium]JSB-HSQC spectra, and pure DMSO-d6 was used as a control in isothermal conditions, as shown in FIG. 14, where the abscissa represents the hydrogen spectrum, the ordinate represents the carbon spectrum, and backstreaming signals in the figure represent the background signal. According to the analysis of the experimental result, all the C-H couplings on the estrone skeleton can be detected in the ordered OPALC medium, which shows that the OPALC medium has good compatibility with the estrone. The RDCs for estrone ranged in size from-10.8 to 30.9Hz (Table 1). To test the accuracy of these RDCs, the present invention uses a Singular Value Decomposition (SVD) method and the MSpin program for theoretical calculations. The Density Functional Theory (DFT) at the level of B3LYP/6-31G (d) was introduced for calculation of theoretical RDCs. The linear relationship between the measured RDCs and the calculated RDCs is shown in FIG. 15, wherein in FIG. 15, Experimental RDCs means experimental RDCs, CalculatedRDCs means calculated RDCs, and Estrone means Estrone. The Q factor of estrone is 0.079 (the lower the Q value, the better the modeled predicted configuration fits its actual configuration), indicating that self-assembled LC is an excellent medium for accurate measurement of RDCs.

Example 3

The compatibility of the aromatic molecule and the self-assembled OPALC is proved by the antineoplastic drug 10-hydroxycamptothecin, so as to further research the applicability of the self-assembled LC as a medium for accurately obtaining the RDCs in DMSO-d 6.

The anti-tumor drug 10-hydroxycamptothecin was used to demonstrate the compatibility of the aromatic molecule with self-assembled OPALC. As shown in FIG. 16, 10.0mg 10-hydroxycamptothecin was dissolved in OPALC (LC concentration 40.0mg/mL), which was²The HNMR spectrum showed RQC to be 25.39 Hz. In fig. 16, the abscissa represents frequency, and the ordinate represents relative intensity. Recording of 10-hydroxycamptothecin using self-assembled LC as ordered Medium¹H,¹³C]JSB-HSQC spectra, and pure DMSO-d6 was used as a control in isothermal conditions, the experimental results are shown in FIG. 17, whose C-13 spectra are given in Table 2, in FIG. 17, the abscissa represents the hydrogen spectrum, the ordinate represents the carbon spectrum, and background signals are meant. The results show that all C-H couplings on the 10-hydroxycamptothecin backbone can be detected in ordered OPALC media, indicating that the OPALC media has good compatibility with 10-hydroxycamptothecin as well. The RDCs of the detected 10-hydroxycamptothecin were-31.7-3.42 Hz (Table 2). The Q factor value obtained by fitting is 0.076, and a low Q factor value indicates that the RDCs value of 10-hydroxycamptothecin can be effectively and accurately measured by using the medium, as shown in FIG. 20, the abscissa represents a hydrogen spectrum, the ordinate represents a carbon spectrum, and background signals are background signals.

TABLE 2

¹³C positioning	δ_Cppm	¹H positioning	δ_Hppm	¹J_CH	¹T_CH	¹D_CH	¹D_CHCalculated value
								C5	50.70	H5a,b	5.21	148.44	-	-	-
C7	129.65	H7	8.42	163.95	140.62	-23.33	-20.98
								C9	109.22	H9	7.26	159.12	134.47	-24.65	-25.20
C11	123.36	H11	7.41	160.90	129.16	-31.74	-31.17
								C12	131.03	H12	8.00	161.86	137.80	-24.06	-25.26
C14	96.29	H14	7.24	172.44	153.15	-19.29	-20.08
								C17	65.70	H17a,b	5.41	152.35	-	-	-
C18	7.90	H18(Me)	0.88	128.08	131.50	3.42	6.52
								C19	30.00	H19a,b	1.86	130.72	129.55	-1.17	-1.52

Example 4

To further investigate the feasibility of OPALC for the analysis of other organic molecular structures, the following discussion will be made with artemisinin as a substrate.

Artemisinin is a potent malaria drug and acquired a physiological or medical reward of nobel in 2015. As shown in FIG. 18, 10.0mg artemisinin was dissolved in OPALC (LC concentration 40.0mg/mL), which was purified²The HNMR spectrum showed RQC to be 21.31 Hz. In fig. 18, the abscissa represents frequency and the ordinate represents relative intensity. Use of self-assembled LC as ordered Medium for the recording of artemisinin¹H,¹³C]JSB-HSQC spectra, and pure DMSO-d6 was used as a control in isothermal conditions, as shown in FIG. 19, whose C-13 spectra are given in Table 3. Artemisinin could be detected as RDCs at-1.71-6.95 Hz (Table 3). An excellent fit was also obtained for Artemisinin, with a low Q factor value of 0.088, as shown in FIG. 21, and in FIGS. 20 and 21, 10-Hydroxycamptothecine represents 10-hydroxycamptothecin and Artemisinin represents Artemisinin.

TABLE 3

¹³C positioning	δ_Cppm	¹H positioning	δ_Hppm	¹J_CH	¹T_CH	¹D_CH	¹D_CHCalculated value
								C1	49.94	H1	1.32	131.76	138.37	6.61	6.81
C2	24.86	H2a,b	1.92,1.32	129.48	131.47	1.99	2.34
								C3	35.92	H3a,b	2.26,2.05	128.55	132.64	4.09	3.66
C5	93.75	H5	6.13	179.25	177.54	-1.71	-1.65
								C7	44.37	H7	1.78	133.10	140.05	6.95	6.58
C8	22.96	H8a,b	1.71,1.14	127.42	130.52	3.10	3.71
								C9	33.53	H9a,b	1.62,1.01	126.90	128.37	1.47	1.74
C10	36.51	H10	1.53	127.00	133.84	6.84	6.82
								C11	32.93	H11	3.16	127.25	126.86	-0.39	-0.50
C13	12.93	H13(Me)	1.06	129.09	128.65	-0.44	-0.14
								C14	20.10	H14(Me)	0.91	126.29	127.07	0.78	1.35
C15	25.56	H15(Me)	1.35	129.86	130.71	0.85	0.91

Compared with the existing peptide LC crystal system, the invention has two advantages:

1) the flexible oligopeptide amphiphile can be constructed, and a thought is provided for designing and developing other novel liquid crystals because the flexible oligopeptide amphiphile does not contain a rigid structure required by the traditional liquid crystal.

2) The solvent for self-assembling peptide LC was pure DMSO.

In view of the above advantages, oligopeptide LC shows great promise in RDCs measurements. The OPA can be automatically synthesized by an instrument, and is easy to prepare; the liquid crystal can be prepared by directly dissolving the oligopeptide, and the method is simple and has strong operability. The absence of rigid aromatic groups in OPA avoids the risk of strong pi-pi interactions between the ordered medium and the analyte. Meanwhile, the solvent used in the system is DMSO, so that the problem that the detected substrate cannot be dissolved in the conventional solvent can be effectively solved, and the variety and the number of the detected substrates are effectively expanded.

Various modifications may be made to the above without departing from the spirit and scope of the invention as defined by the appended claims. The scope of the invention is therefore intended to be limited not by the above description, but rather by the scope of the appended claims.

Claims

1. A novel lyotropic liquid crystal based on self-assembly of amphiphilic oligopeptide, which is characterized in that the oligopeptide has the structural formula as follows:

and adding the oligopeptide into a pure DMSO solvent, performing direct ultrasonic full dissolution, and assembling to obtain the novel lyotropic liquid crystal, wherein the particle size of the oligopeptide is 120nm or 550 nm.

2. The novel lyotropic liquid crystal of claim 1, wherein said oligopeptide is flexible.

3. The amphiphilic oligopeptide-based self-assembly novel lyotropic liquid crystal according to claim 1, wherein the novel lyotropic liquid crystal shows 5-76Hz residual quadrupole coupling by deuterium resonance in DMSO-d6 solution when the concentration of the oligopeptide is 2-10 wt%, and the degree of order can be controlled by the concentration of the oligopeptide.

4. Use of the RDCs according to claim 1 for measuring biomolecules based on the self-assembly of amphiphilic oligopeptides into novel lyotropic liquid crystals as ordered media.

5. The use according to claim 4, wherein the liquid crystal is capable of measuring RDCs of biomolecules based on deuterated dimethylsulfoxide (DMSO-d6) solvent system, and analyzing the structure of the biomolecules.

6. The use according to claim 5, wherein the liquid crystal is capable of measuring the RDCs of estrone and analyzing the structure of estrone.

7. The use of claim 5, wherein said liquid crystal is capable of measuring the RDCs of 10-hydroxycamptothecin, and analyzing the structure of 10-hydroxycamptothecin.

8. The use according to claim 5, wherein the medium is capable of measuring the RDCs of artemisinin and analyzing the structure of artemisinin.